Innovations in Vaccine Technology
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Attenuated/Inactivated/Live and Vectored Vaccines".
Deadline for manuscript submissions: 31 May 2025 | Viewed by 1574
Special Issue Editor
Interests: peptides; subunit vaccines; vaccine development; infectious diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Advances in vaccine technology have improved our ability to prevent infectious diseases, revolutionizing global public health. Scientists have pursued safe and more effective immunization strategies from traditional approaches such as attenuated or inactivated vaccines to modern techniques such as mRNA and viral vector vaccines. These innovations have increased our capacity to respond to emerging threats such as pandemics. In addition, innovations in vaccine delivery systems, adjuvants and formulation techniques have further improved vaccine efficacy, safety and accessibility. Moreover, the integration of computational modeling, artificial intelligence and bioinformatics has made it easier to design and optimize novel vaccine candidates.
This Special Issue focuses on groundbreaking research and discoveries in the field of vaccine technology. We are inviting researchers, clinicians and stakeholders to contribute their insights and findings that drive forward the frontier of immunization and improve health.
Dr. Rachel Stephenson
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inactivated vaccines
- live-attenuated vaccines
- messenger RNA (mRNA) vaccines
- subunit, recombinant, polysaccharide and conjugate vaccines
- toxoid vaccines
- viral vector vaccines
- personalized vaccines
- antigen design
- reverse vaccinology
- lipid nanoparticles
- cell-based vaccine production
- virus-like particles
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
